Biocon banks on new biosimilar launches, insulin franchise to drive stronger H2 FY27

According to Chief Executive Officer and Managing Director Shreehas Tambe, around $20 million (around Rs.200 crore) of quarterly biosimilars revenue could not be recognised in Q2…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.moneycontrol.com)